UCSF Experimental Cellular Therapy Group

The UCSF Experimental Cellular Therapy Group is composed of investigators at UCSF and affiliated institutions who develop new cellular therapy products and manufacture these products to support phase 1 clinical trials. We have expertise in every aspect of cellular therapy drug development from setting initial product specifications through manufacturing for clinical trials. We develop and implement new approaches and technologies to improve the efficiency and safety of cellular therapy development. There are many opportunities for training. The group is coordinated by Dr. Jonathan Esensten, Assistant Adjunct Professor in the Department of Laboratory Medicine. For inquiries, please email [email protected]

Principle investigators and sponsoring institutions for current cellular therapy projects:

Jeffrey Bluestone, PhD, UCSF

Qizhi Tang, PhD, UCSF

Regulatory T cell therapies

Alexander Marson MD, PhD, UCSF

Innovative Genomics Institute

CRISPR/Cas9 gene modified T cell therapies

Hideho Okada, MD, PhD, UCSF

Lisa Butterfied, PhD, Parker Institute for Cancer Immunotherapy

T cell therapy for glioblastoma

Susan Fisher, PhD, UCSF

Novo Nordisk

Embryonic stem cells